Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | CFTR | P13569 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7191685 | 0.90 | L3MBTL1 (0.49) | L3MBTL1ALDH1A1MAPTKDM4EGAA | |
| SCHEMBL20198518 | 0.88 | MAPT (0.47) | L3MBTL1ALDH1A1MAPTKDM4EGAA | |
| SCHEMBL29699082 | 0.87 | KDM4E (0.39) | L3MBTL1ALDH1A1MAPTKDM4EGAA | |
| SCHEMBL376223 | 0.87 | KDM4E (0.39) | L3MBTL1ALDH1A1MAPTKDM4EGAA | |
| SCHEMBL356817 | 0.87 | LMNA (0.43) | L3MBTL1ALDH1A1MAPTKDM4EGAA | |
| SCHEMBL356011 | 0.86 | ALDH1A1 (0.54) | L3MBTL1ALDH1A1MAPTKDM4EGAA | |
| SCHEMBL28367018 | 0.84 | KDM4E (0.37) | L3MBTL1ALDH1A1MAPTKDM4EGAA | |
| SCHEMBL5023620 | 0.83 | ALDH1A1 (0.51) | L3MBTL1ALDH1A1MAPTKDM4EGAA | |
| SCHEMBL28991315 | 0.83 | KDM4E (0.36) | L3MBTL1ALDH1A1MAPTKDM4EGAA | |
| SCHEMBL3469834 | 0.83 | KDM4E (0.42) | L3MBTL1ALDH1A1MAPTKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9895376-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2018-02-20 | — | — | US | disclosed |
| US-20160206621-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2016-07-21 | — | — | US | disclosed |
| US-9273046-B2 | Fused tricyclic compounds as Raf kinase inhibitors | BEIGENE, LTD. (KY) | 2016-03-01 | — | — | US | disclosed |
| US-20150045355-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2015-02-12 | — | — | US | disclosed |
| EP-2424856-B1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2014-12-31 | — | — | EP | disclosed |
| EP-2424856-B1 | FUSED HETEROCYCLIC COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2014-12-31 | — | — | EP | disclosed |
| US-8461181-B2 | Fused heterocyclic compound and use thereof | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8461181-B2 | Fused heterocyclic compound and use thereof | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2013-06-11 | — | — | US | disclosed |
| US-8273764-B2 | Fused heterocyclic compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-8273764-B2 | Fused heterocyclic compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-09-25 | — | — | US | disclosed |
| US-20070099899-A1 | Heterocyclic dihydropyrimidine compounds | ATWAL KARNAIL S | 2007-05-03 | — | — | US | disclosed |
| US-7157451-B2 | Heterocyclic dihydropyrimidine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157451-B2 | Heterocyclic dihydropyrimidine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157451-B2 | Heterocyclic dihydropyrimidine compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040063687-A1 | Heterocyclic dihydropyrimidine compounds | ATWAL KARNAIL S (US) | 2004-04-01 | — | — | US | disclosed |
| US-6706720-B2 | TREATMENT OF ARRHYTHMIA; INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-16 | — | — | US | disclosed |
| CN-1407985-A | Heterocyclic dihydropyrimidines as potassium channel inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2003-04-02 | — | — | CN | disclosed |
| US-20030022890-A1 | Heterocyclic dihydropyrimidine compounds | PEDESTRIAN CONCEPTS LLC | 2003-01-30 | — | — | US | disclosed |
| EP-1237891-A1 | HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2001040231-A1 | HETEROCYCLIC DIHYDROPYRIMIDINES AS POTASSIUM CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160206621-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | L3MBTL1 1159/4885ALDH1A1 2551/4885MAPT 3008/4885 |
| US-20040063687-A1 | Heterocyclic dihydropyrimidine compounds | KCNJ2, KCNH2, KCNH1 | L3MBTL1 1779/4885ALDH1A1 2042/4885MAPT 3600/4885 |
| US-20030022890-A1 | Heterocyclic dihydropyrimidine compounds | KCNJ2, KCNH2, KCNH1 | L3MBTL1 1779/4885ALDH1A1 2042/4885MAPT 3600/4885 |
| US-20070099899-A1 | Heterocyclic dihydropyrimidine compounds | KCNJ2, KCNQ5, KCNQ2 | L3MBTL1 1280/4885ALDH1A1 2928/4885MAPT 3321/4885 |
| US-20150045355-A1 | FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | L3MBTL1 1159/4885ALDH1A1 2551/4885MAPT 3008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.